Joseph Schwartz, an analyst from Leerink Partners, reiterated the Hold rating on PTC Therapeutics (PTCT – Research Report). The ...

Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $43 from $31 and keeps an Equal Weight rating on the shares. The ...

Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in ...

In a statement to Windows Central, Microsoft has confirmed that it's unifying its news content services under the MSN brand once again.

BOSTON (AP) — BOSTON (AP) — PTC Inc. (PTC) on Wednesday reported fiscal fourth-quarter earnings of $126.5 million. The Boston-based company said it had net income of $1.04 per share.

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock Oppenheimer has initiated coverage on Larimar Therapeutics ...

For the quarter, PTC anticipates revenues to be between $598 million and $648 million. Non-GAAP earnings per share (EPS) are expected to be between $1.30 and $1.66. The Zacks Consensus Estimate ...

The biopharmaceutical company posted revenue of $196.8 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $173.5 million. PTC Therapeutics expects full-year ...

BOSTON (AP) — BOSTON (AP) — PTC Inc. (PTC) on Wednesday reported fiscal fourth-quarter earnings of $126.5 million. The Boston-based company said it had net income of $1.04 per share. Earnings, ...

PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on ...